{"id":"NCT02483585","sponsor":"Amgen","briefTitle":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-20","primaryCompletion":"2016-07-11","completion":"2017-03-20","firstPosted":"2015-06-29","resultsPosted":"2018-06-25","lastUpdate":"2022-10-12"},"enrollment":577,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Erenumab","otherNames":["AMG 334","Aimovigâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Erenumab","type":"EXPERIMENTAL"}],"summary":"To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.","primaryOutcome":{"measure":"Change From Baseline in Monthly Migraine Days at Week 12","timeFrame":"4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase","effectByArm":[{"arm":"Placebo","deltaMin":-1.84,"sd":0.21},{"arm":"Erenumab 70 mg QM","deltaMin":-2.88,"sd":0.21}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":76,"countries":["United States","Denmark","France","Greece","Portugal","Russia","Spain","Switzerland"]},"refs":{"pmids":["29471679","35272533","35137394","31707815","31852816","35978286","34928306"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":289},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Injection site pain","Migraine"]}}